Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial

COVID-19, being a life-threatening infection that evolves rapidly, remains a major public health concern calling for the development of vaccines with broad protection against different pathogenic strains and high immunogenicity. Aside from this, other concerns in mass immunization settings are also...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudriavtsev, Aleksandr V., Vakhrusheva, Anna V., Kryuchkov, Nickolay A., Frolova, Maria E., Blagodatskikh, Konstantin A., Ivanishin, Taras V., Djonovic, Milana, Romanovskaya-Romanko, Ekaterina A., Kovalenko, Anton N., Lioznov, Dmitry A., Zubkova, Tatiana G., Teplykh, Svetlana V., Oseshnyuk, Rodion A., Stukova, Marina A., Isaev, Artur A., Krasilnikov, Igor V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965088/
https://www.ncbi.nlm.nih.gov/pubmed/36851204
http://dx.doi.org/10.3390/vaccines11020326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965088/
https://www.ncbi.nlm.nih.gov/pubmed/36851204
http://dx.doi.org/10.3390/vaccines11020326

Ejemplares similares